Case study: Angiotensin receptor blockers (ARBs)

here is now also ample evidence that the "residence time" of a drug at it cellular target (such as a receptor or an enzyme) may affect its clinical performance. In this respect, a great deal of attention has been devoted to those situations in where optimal clinical performance requires continuing, high levels of target occupancy. This has for example been proposed to be the case with AT1 receptor antagonist candesartan.

ISBN:978-3-527-33582-4

Publication year:2015

Keywords:angiotensin receptors, radioligand binding, sartans, rebinding, binding kinetics